Abstract
A register‐based cohort study conducted in Sweden found that lisdexamfetamine was the only studied treatment associated with reduced risk of hospitalization and death in patients with amphetamine or methamphetamine use disorder. Use of benzodiazepines was associated with significantly higher risk of hospitalization and death, the investigators reported. Study results were published online Nov. 16, 2022, in JAMA Psychiatry.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
